Vanguard Portfolio Management
GYRE icon

Vanguard Portfolio Management’s Gyre Therapeutics GYRE Stock Holding History

Vanguard Portfolio Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$817K Buy
123,953
+54,139
+78% +$369K ﹤0.01% 3002
2026
Q1 		$487K Buy
+69,814
New +$542K ﹤0.01% 2952

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Portfolio Management's GYRE Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Gyre Therapeutics (GYRE) stake by 78% in Q2 2026, buying an estimated $369K and bringing the position to 123,953 shares worth $817K. The position accounts for ﹤0.01% of the portfolio, ranked #3002.

Vanguard Portfolio Management first reported a position in GYRE in Q1 2026 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Vanguard Portfolio Management held 123,953 shares of Gyre Therapeutics worth $817K as of Q2 2026.
  • Vanguard Portfolio Management bought 54,139 Gyre Therapeutics shares in Q2 2026, an estimated $369K.
  • Gyre Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #3002 holding.
  • Vanguard Portfolio Management first reported a position in Gyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.